Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

P3 Health Partners (PIIIW) EBIT (2020 - 2025)

P3 Health Partners' EBIT history spans 6 years, with the latest figure at -$153.9 million for Q4 2025.

  • For Q4 2025, EBIT fell 11.09% year-over-year to -$153.9 million; the TTM value through Dec 2025 reached -$270.3 million, up 15.7%, while the annual FY2025 figure was -$270.3 million, 15.7% up from the prior year.
  • EBIT reached -$153.9 million in Q4 2025 per PIIIW's latest filing, down from -$44.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $36.3 million in Q4 2021 to a low of -$912.2 million in Q2 2022.
  • Average EBIT over 5 years is -$116.6 million, with a median of -$44.0 million recorded in 2024.
  • Peak YoY movement for EBIT: tumbled 13862.85% in 2022, then skyrocketed 97.69% in 2023.
  • A 5-year view of EBIT shows it stood at $36.3 million in 2021, then crashed by 1576.5% to -$536.5 million in 2022, then soared by 88.02% to -$64.3 million in 2023, then tumbled by 115.54% to -$138.5 million in 2024, then dropped by 11.09% to -$153.9 million in 2025.
  • Per Business Quant, the three most recent readings for PIIIW's EBIT are -$153.9 million (Q4 2025), -$44.2 million (Q3 2025), and -$34.1 million (Q2 2025).